ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout
Lilly's Jake Van Naarden is meeting myeloma experts at ASCO to figure out the best possible path for phase 3 trials of Kelonia's in vivo CAR-T prospect. (Darren Incorvaia) Kelonia Therapeutics has ...
WASHINGTON, May 28 (Reuters) - U.S. forces deployed to war zones have been targeted using commercially available location data, according to reports fielded by military officials, an illustration of ...
Kassi Solberg has concerns about a proposed complex, the size of 3,800 football fields, near her home. Trust us, the developer says. “I hope I will be able to make a difference,” said Kassi Solberg, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results